Chidamide With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer

Chidamide With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer: An Open-label, Single-armed Phase II Trial

NCT02815007•Yuankai Shi

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer

Interventions

Chidamide with EGFR-TKI

Key Dates

Start Date

June 1, 2016

Primary Completion Date

March 1, 2018

Completion Date

June 1, 2018

Last Updated

June 28, 2016

Contacts

Yuankai Shi, Doctor

CONTACT

86-015821531560 drshiyuankai@163.com

Sponsors

Lead Sponsor

Yuankai Shi

Detailed Description

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 28, 2016Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions